CLINICAL_TRIALS
trial_result
· 2015-11-02
Clinical Trial Update: GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026) [Phase 2]
Summary
A Phase 2 trial comparing GEM at 1.5 mg twice daily and 4.5 mg twice daily to lorazepam for generalized anxiety disorder has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Anxiety Disorder | Phase 2 | Status: COMPLETED